公开(公告)号：ES2403413T3

公开(公告)日：2013-05-17

申请号：ES08839610

申请日：2008-10-16

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID ,  PURRO NORBERT

IPC: C07K14/76 ,  A61K31/4164 ,  A61K35/14 ,  A61K38/48 ,  A61K41/00 ,  A61K45/06 ,  A61M5/178 ,  C07D209/00 ,  C07K14/00

Abstract: Una composición en una forma adecuada para administración subcutánea a un mamífero que comprende uncompuesto de la Fórmula I o una sal del mismo disuelto en agua: **Fórmula** comprendiendo la solución adicionalmente hidróxido de sodio y trometamina, en donde la composición tiene un pHentre 8.0 y 9.5.

公开(公告)号：NZ579911A

公开(公告)日：2012-05-25

申请号：NZ57991108

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: C07D473/34 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  C07D253/06 ,  C07D487/04

Abstract: Disclosed are irreversible tyrosine kinase inhibitor compounds of Formula (I) (1H-pyrazolo[3,4-d] pyrimidine), wherein the substituents are as described within the specification. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), and the use of a compound of Formula (I) for the manufacture of a medicament for the treatment of an autoimmune disorder, a heteroimmune disorder, inflammation, rheumatoid arthritis, lupus, allergies, type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, atopic dermatitis, B-cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or a combination thereof.

公开(公告)号：HK1147267A1

公开(公告)日：2011-08-05

申请号：HK11101423

申请日：2011-02-15

Applicant: PHARMACYCLICS INC

Inventor： LOURY DAVID ,  PURRO NORBERT

IPC: C07K20060101 ,  A61K20060101

Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:

公开(公告)号：MX2011000661A

公开(公告)日：2011-05-25

申请号：MX2011000661

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID

IPC: A61K31/52 ,  A61P35/00

Abstract: Descritos en la presente, son compuestos inhibidores de Btk irreversibles, y métodos para el uso de dichos inhibidores irreversibles, en el tratamiento de enfermedades y trastornos caracterizados por la presencia o el desarrollo de tumores sólidos.

公开(公告)号：AU2009270856A8

公开(公告)日：2011-03-03

申请号：AU2009270856

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  CHEN WEI ,  BUGGY JOSEPH ,  LOURY DAVID ,  VERNER ERIK

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.

公开(公告)号：CA2730930A1

公开(公告)日：2010-01-21

申请号：CA2730930

申请日：2009-07-16

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61P35/00

Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.